FIG. 7.
Tyrosines within TFII-I are important for its contribution to Bright activity. (a) Extracts (Ext) from the human B-cell line CL01 (lane 4) were immunoprecipitated (IP) with anti-TFII-I (lane 1), anti-human Bright (Anti-HuBr) (lane 2), or control goat Ig (Anti-GtIg) (lane 3), Western blotted (immunoblotted [IB]), and developed with anti-pTyr or anti-TFII-I antibodies. The 120 and 128 isoforms of TFII-I are identified. (b) Quantitative real-time PCR was used to measure IgH mRNA in sorted GFP+ cells transfected with a reporter plasmid and expression vectors for Bright, Btk, and either wild-type TFII-I or the YY248/249FF (YY/FF) mutant form of TFII-I. Control cells (Ctl) were transfected with the same quantity of DNA but used empty vectors with the reporter plasmid. GAPDH CT values from triplicate experiments varied from 23 to 25 among the three transfected groups. Data were taken from three independent experiments. Standard error bars are indicated.